ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ:AMRI) and CHDI Foundation, Inc., a non-profit organization pursuing drugs that delay or slow Huntington’s disease (HD), announced today the commencement of a new collaboration agreement focused on the discovery of new therapeutic agents for the treatment of this disease.
